SomaSignal Tests for Diabetes

About SomaLogic

Founded in 2000, SomaLogic's mission is to decode the human proteome to revolutionize life sciences and healthcare. Its core achievement is the SomaScan Platform, which leverages proprietary SOMAmer® reagents and KREX™ technology to deliver unparalleled scale, sensitivity, and reproducibility in protein measurement. The company's strategy focuses on providing fee-for-service assay services globally, expanding its menu of SomaSignal diagnostic tests, and leveraging its 2024 merger with Standard BioTools to accelerate leadership in integrated multi-omics solutions.

Therapeutic Areas